Overview

Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

Status:
Recruiting
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the safety of ex vivo expanded haploidentical natural killer (NK) cells for patients with leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Treatments:
Interleukin-2